A population-scale signal is beginning to emerge
New data summarized by Gizmodo points to an inflection point in the U.S. obesity story. According to trackers released by EPIC Research using the COSMOS medical-records dataset, prescriptions for GLP-1 drugs have risen sharply in recent years while the share of people with obesity in the dataset has edged downward.
The headline shift is modest, not dramatic. But after years of stubbornly high obesity rates, even a small sustained decline carries weight. The reported figures show GLP-1 prescriptions among U.S. adults rising from 1,884 to 8,819 per 100,000 patients between the second quarter of 2021 and the first quarter of 2026. Over the same period, the percentage of people with obesity in the dataset fell from 42% to 41%.
That single percentage point will not, on its own, settle the debate over how deeply anti-obesity medicines can reshape public health. It does, however, offer something the GLP-1 discussion has often lacked: evidence that adoption may be visible at scale rather than only in clinical trials or individual outcomes.
Why the dataset matters
The source text describes COSMOS as a collaboration built from electronic medical records across thousands of hospitals and clinics, covering more than 300 million patient records in the U.S. and other countries. That breadth does not make it a perfect mirror of the nation, but it does give researchers a large and continuously updated view of care patterns.
In this case, the value is not just in counting prescriptions. It is in linking prescribing trends to body-mass-index trends over time. The article notes that the obesity decline was larger among people who had previously received a GLP-1 prescription, with obesity in that subgroup falling from 75% to 69%.
That pattern is consistent with what physicians and patients already know from the clinical side: these drugs can be effective tools for weight loss and for reducing some obesity-linked health risks while patients remain on treatment. What is newly notable is the possibility that uptake is becoming large enough to register in population data.
A turning point, but not a conclusion
It would be premature to say GLP-1 medicines have solved obesity. The source itself is careful on that point. The drop is small, and the dataset is not necessarily representative of the entire country. There are also major unanswered questions around long-term adherence, access, insurance coverage, side effects, and what happens when patients stop treatment.
Still, the direction of travel matters. U.S. obesity rates rose for years with remarkable persistence. Reversing that pattern was never likely to happen all at once. If a medication class is helping push the curve downward, even gradually, that is a meaningful development.
The broader implication is that obesity treatment may be shifting from a frustratingly static public-health challenge to a more dynamic market and care-delivery problem. Once effective drugs exist, the central questions become who gets them, who can afford them, how long they stay on them, and whether health systems can support long-term management rather than short bursts of use.
What comes next
The next phase of the story will hinge on durability. A fourfold rise in prescribing is a major change, but the deeper test is whether those prescriptions remain widespread enough, and sustained enough, to keep bending outcomes over multiple years. Researchers will also need better clarity on subgroup effects, discontinuation rates, and whether improvements extend beyond BMI into complications tied to obesity.
For now, the strongest conclusion is also the simplest one: in a large real-world dataset, GLP-1 uptake is rising fast, and obesity rates are no longer moving only in the old direction. That does not end the crisis. But it may mark the first credible sign that the curve can be pushed the other way.
- EPIC Research data shows GLP-1 prescriptions rising sharply from 2021 to 2026.
- The obesity rate in the dataset fell modestly from 42% to 41% over the same period.
- The data suggests a population-level effect may be emerging, though long-term outcomes remain uncertain.
This article is based on reporting by Gizmodo. Read the original article.
Originally published on gizmodo.com
